FDA Panel Nod For PFE, INSM Withdraws MAA, FCSC's Voice Fades Out

Pfizer Inc.'s (PFE) ALO-02 has been recommended by an FDA panel for its proposed indication, "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate".

from RTT - Biotech http://ift.tt/24BvYRF
via IFTTT